Compare NECB & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NECB | SLN |
|---|---|---|
| Founded | 1934 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.4M | 318.4M |
| IPO Year | N/A | N/A |
| Metric | NECB | SLN |
|---|---|---|
| Price | $23.06 | $6.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $39.67 |
| AVG Volume (30 Days) | 48.7K | ★ 309.7K |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.21 | N/A |
| Revenue | ★ $102,569,000.00 | $25,830,000.00 |
| Revenue This Year | $1.90 | N/A |
| Revenue Next Year | $6.93 | N/A |
| P/E Ratio | $7.12 | ★ N/A |
| Revenue Growth | N/A | ★ 40.39 |
| 52 Week Low | $19.27 | $1.97 |
| 52 Week High | $25.93 | $8.08 |
| Indicator | NECB | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 44.28 |
| Support Level | $22.81 | $6.11 |
| Resistance Level | $24.13 | $6.59 |
| Average True Range (ATR) | 0.63 | 0.45 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 55.85 | 12.87 |
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.